GLP-1 Weight-Loss Drugs May Reduce Heart Attack and Stroke Risk by 13%, Study Finds
If you or someone you love is taking a GLP-1 medication like Ozempic, Wegovy, or Mounjaro, there is compelling new evidence that the benefits go far beyond weight loss. A major new analysis suggests these drugs may also significantly protect your heart.
What the Research Found
Scientists at Anglia Ruskin University analyzed data from more than 90,000 patients across 11 large international clinical trials. Their findings, published in Cardiovascular Diabetology in May 2026, showed that people taking GLP-1 receptor agonists had a 13% lower risk of major cardiovascular events — including heart attacks, strokes, and cardiovascular death — compared to those who received a placebo.
This was not a small or short-term study. Only trials with at least one year of follow-up were included, meaning these are sustained, long-term benefits — not temporary effects.
Who Benefits Most?
The cardiovascular benefits were most pronounced in people already at elevated risk, including those with type 2 diabetes, obesity, or existing heart disease. Importantly, the reduced risk was seen regardless of whether patients had diabetes, suggesting the heart-protective effects are not simply a result of better blood sugar control.
People taking GLP-1 drugs also experienced fewer nonfatal heart attacks, fewer nonfatal strokes, fewer hospitalizations for heart failure, and a lower risk of death from any cause.
Which Drugs Were Studied?
The analysis covered several GLP-1 receptor agonists currently in widespread use, including semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and dulaglutide (Trulicity). Benefits were consistent across all drugs studied, regardless of the specific medication or trial design.
Are These Drugs Safe Long-Term?
One of the most common concerns people have when starting a GLP-1 medication is the question of long-term safety. This study offers some reassurance: researchers did not find a meaningful increase in serious side effects, including severe hypoglycemia or pancreatitis, compared to placebo. Gastrointestinal side effects such as nausea were more common, but these are already well-documented and typically improve over time.
What This Means for You
Lead researcher Dr. Simon Cork of Anglia Ruskin University said: “These drugs have the potential to become a key part of healthcare strategies, especially for people with type 2 diabetes or established heart disease. Using them earlier and more widely across populations could help prevent thousands of serious cardiovascular events.”
If you are currently taking a GLP-1 medication and wondering whether it is the right long-term choice, this research suggests the answer may be yes — not just for your waistline, but for your heart as well. As always, talk to your doctor about what is right for your individual health situation.
Source: Peter K, et al. “The long-term cardiovascular safety and efficacy of glucagon-like peptide-1 receptor agonists in high-risk cardiovascular populations: a systematic review and meta-analysis.” Cardiovascular Diabetology, May 1, 2026.
